Long-term safety of biologics in the treatment of psoriasis

References

• Nestle FO, Kaplan DH, Barker J. Mechanisms of disease psoriasis. N Engl J Med. 2009;361:496–509.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Psoriasis: full guideline. Available from: http://www.nice.org.uk/guidance/index.jsp?action=download&o=59182. Accessed April 12, 2013.
   Google Scholar
• Pietrzak A, Bartosinska J, Chodorowska G, Szepietowski JC, Paluszkiewicz P, Schwartz RA. Cardiovascular aspects of psoriasis: an updated review. Int J Dermatol. 2013;52:153–162.
   PubMed Web of Science ®Google Scholar
• Alexandroff AB, Pauriah M, Camp RD, Lang CC, Struthers AD, Armstrong DJ. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol. 2009;161:1–7.
   PubMed Web of Science ®Google Scholar
• Archier E, Devaux S, Castela E, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26 Suppl 3:22–31.
   Google Scholar
• British Association of Dermatologists. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis; 2009. Available from: http://www.bad.org.uk/Portals/_Bad/Guidelines/Clinical%20Guidelines/Biologics%20guidelines%202009.pdf. Accessed April 12, 2013.
   Google Scholar
• Zhu J, Paul WE. Heterogeneity and plasticity of T helper cells. Cell Res. 2010;20:4–12.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Etanercept and efalizumab for the treatment of adults with psoriasis; 2006. Available from: http://www.nice.org.uk/nicemedia/live/11580/33376/33376.pdf. Accessed April 12, 2013.
   Google Scholar
• Tyring S, Gordon KB, Poulin Y, et al. Long term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143:719–726.
   PubMed Web of Science ®Google Scholar
• Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimes for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340:c147.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Strober BE, Van De Kerkhof P. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118–128.
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Griffiths CEM, Dauden, et al. Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study. Exp Rev Dermatol. 2008;3:657–665.
   Google Scholar
• National Institute for Health and Clinical Excellence. Psoriasis – infliximab for the treatment of psoriasis. Available from: http://www.nice.org.uk/ta134. Accessed April 12, 2013.
   Google Scholar
• Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs methotrexate in patients with moderate to severe psoriasis: results of an open-label, active-controlled randomized trial (RESTORE 1). Br J Dermatol. 2011;165:1109–1117.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Psoriasis – adalimumab technology. Appraisal 146. Available from: http://www.nice.org.uk/ta146. Accessed April 12, 2013.
   Google Scholar
• Thaci D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol. 2010;163:402–411.
   PubMed Web of Science ®Google Scholar
• Reich K, Signorovitch J, Ramakrishnan K, et al. Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial. J Am Acad Dermatol. 2010;63:1011–1018.
   PubMed Web of Science ®Google Scholar
• Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010;63:448–456.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Psoriasis – ustekinumab technology. Appraisal 180. Available from: http://www.nice.org.uk/nicemedia/live/12235/45461/45461.pdf. Accessed April 12, 2013.
   Google Scholar
• Medicines Compendium UK. Ustekinumab Standard of Product Characteristics. Available from: http://www.medicines.org.uk/EMC/medicine/23207/SPC/Stelara+45+mg+solution+for+injection+in+pre-filled+syringe/. Accessed April 12, 2013.
   Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665–1674.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Griffiths CE, et al. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012;11:300–312.
   PubMed Web of Science ®Google Scholar
• Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306:864–871.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735–1741.
   PubMed Web of Science ®Google Scholar
• Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829–835.
   PubMed Web of Science ®Google Scholar
• Menter A, Griffiths CE, Tebbey PW, Horn EJ, Sterry W; International Psoriasis Council. Exploring the association between cardiovascular and other disease related risk factors in the psoriasis population: the need for increased understanding across the medical community. J Eur Acad Dermatol Venereol. 2010;24:1371–1377.
   Web of Science ®Google Scholar
• Tzellos T, Kyrgidis A, Zouboulis C. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trial. J Eur Acad Dermatol Venereol. March 8, 2012. [Epub ahead of print.]
   Web of Science ®Google Scholar
• European Medicines Agency. Abbott Laboratories Limited withdraws its marketing authorisation application for Ozespa (briakinumab). Press release, January 17, 2011. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/01/WC500100769.pdf. Accessed April 12, 2013.
   Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17 receptor antibody for psoriasis. N Engl J Med. 2012;336:1181–1189.
   Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;336:1190–1199.
   Google Scholar
• Rich P, Sigurgeirsson B, Thaci DP, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. September 29, 2013. [Epub ahead of print.]
   Web of Science ®Google Scholar
• Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167:668–677.
   PubMed Web of Science ®Google Scholar